• About
    • Who We Are
    • Leadership Team
    • Board of Directors
    • Clinical and Scientific Advisors
    • Contact
  • Science
    • Immune Continuum
    • CCR4 in Cancer
    • CCR4 in Inflammation
    • HPK1
    • Publications
  • Pipeline
    • Snapshot
    • FLX475
    • RPT193
    • HPK1
    • Discovery Programs
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Email Alerts
    • Investor Contact
    • Investor FAQs
  • Careers
    • Culture
    • Benefits
    • Open Positions

PRESS RELEASES

Year
May 25 | 2022
RAPT Therapeutics Announces Private Placement Financing of $50 Million
May 23 | 2022
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
May 11 | 2022
RAPT Therapeutics Reports First Quarter 2022 Financial Results
May 04 | 2022
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
March 28 | 2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
March 10 | 2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
February 09 | 2022
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
January 04 | 2022
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Contact Us
+1.650.489.9000
inquiries@rapt.com
  • Home
  • About
  • Science
  • Pipeline
  • Investors & Media
  • Careers
  • Terms Of Use
  • Privacy Policy

RAPT Therapeutics
561 Eccles Avenue
South San Francisco, CA 94080
Tel: +1 650 489 9000
Email: inquiries@rapt.com

RAPT Therapeutics, formerly known as FLX Bio.

© 2022 RAPT Therapeutics. All right reserved.